Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- BUSINESS NEWS IN BRIEF
May 18, 2009
- Highlights of 97th JUA Annual Meeting
May 18, 2009
- IMS Proposes Shift of Focus to Emerging Markets
May 18, 2009
- Applied Therapeutics Society Inaugurated
May 18, 2009
- Alfresa to Reduce SGA Cost Ratio to 5-5.5%
May 18, 2009
- Survey Reveals Low Awareness Rates for OTC Drugs, Self-Medication
May 18, 2009
- Price Settlement Rate Stood at 98% as of the End of FY2008
May 18, 2009
- On-line Sale of Class 2 OTC Drugs to Be Permitted for 2 Years
May 18, 2009
- Torii: Sales Down 8.6% Due to Transfer of Stronger Neo Minophagen
May 18, 2009
- Taisho to Enter Market for Topical OTC NSAIDs with Diclotect
May 18, 2009
- Teijin Aims at ¥400 Bil. Sales for Drugs, Home Healthcare Business in 2020
May 18, 2009
- Novartis Launches Switch OTC Voltaren
May 18, 2009
- Merger Boosts Kyowa Kirin's Sales, Profits
May 18, 2009
- 18 APIs to Be Recommended as Switch OTC Drugs
May 18, 2009
- MTPC Aims at Restoring Public's Confidence, Developing Global Products: New President-elect Dr Tsuchiya
May 18, 2009
- R&D NEWS IN BRIEF
May 18, 2009
- Japan Provides High-Quality Data in Multinational Trials: Prof. Sato
May 18, 2009
- JPMA to Support Development of 14 Unapproved Drugs
May 18, 2009
- Nichi-Iko Opens New Office in Tokyo
May 18, 2009
- Enhance Japan's Presence in Multinational Clinical Trials
May 4, 2009
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…